| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
379.52(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-06-29 |
4 |
AS |
$12.00 |
$65,546 |
D/D |
(5,462) |
17,700 |
|
-12% |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-06-29 |
4 |
OE |
$2.60 |
$14,201 |
D/D |
5,462 |
23,162 |
|
- |
|
| Jorkasky Diane |
Director |
– • – |
2022-06-27 |
4 |
AS |
$11.75 |
$206,944 |
D/D |
(17,610) |
0 |
|
1% |
|
| Jorkasky Diane |
Director |
– • – |
2022-06-27 |
4 |
OE |
$3.15 |
$55,472 |
D/D |
17,610 |
17,610 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-06-27 |
4 |
AS |
$12.00 |
$448,254 |
D/D |
(37,352) |
17,700 |
|
1% |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-06-27 |
4 |
OE |
$1.92 |
$79,752 |
D/D |
37,352 |
55,052 |
|
- |
|
| Schafer Klaus |
Director |
– • – |
2022-06-20 |
4 |
OE |
$2.40 |
$670 |
D/D |
279 |
9,179 |
|
- |
|
| Drutz David |
Director |
– • – |
2022-06-15 |
4 |
B |
$8.00 |
$8,000 |
D/D |
1,000 |
20,012 |
2.39 |
36% |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-05-30 |
4 |
D |
$5.03 |
$15,130 |
D/D |
(3,008) |
280,818 |
|
- |
|
| Drutz David |
Director |
– • – |
2022-05-24 |
4 |
B |
$4.50 |
$5,400 |
D/D |
1,200 |
19,012 |
2.39 |
175% |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-04-30 |
4 |
D |
$4.52 |
$13,596 |
D/D |
(3,008) |
283,826 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-03-30 |
4 |
D |
$6.05 |
$18,192 |
D/D |
(3,007) |
286,834 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-02-28 |
4 |
AS |
$7.52 |
$225,600 |
D/D |
(30,000) |
11,545 |
|
71% |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-02-28 |
4 |
OE |
$1.92 |
$57,639 |
D/D |
30,000 |
41,545 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-02-28 |
4 |
D |
$7.41 |
$22,282 |
D/D |
(3,007) |
289,841 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-02-01 |
4 |
D |
$7.98 |
$17,420 |
D/D |
(2,183) |
11,545 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
13,728 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-02-01 |
4 |
D |
$7.98 |
$61,087 |
D/D |
(7,655) |
292,848 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,545 |
300,503 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-02-01 |
4 |
D |
$7.98 |
$17,420 |
D/D |
(2,183) |
17,700 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
19,883 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2022-01-31 |
4 |
A |
$6.86 |
$12,348 |
D/D |
1,800 |
7,562 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-01-31 |
4 |
A |
$6.86 |
$18,913 |
D/D |
2,757 |
283,958 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2022-01-31 |
4 |
A |
$6.86 |
$14,447 |
D/D |
2,106 |
13,717 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2022-01-30 |
4 |
D |
$7.20 |
$16,956 |
D/D |
(2,355) |
281,201 |
|
- |
|
417 Records found
|
|
Page 4 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.56 (7.82%) 
